KORU MEDICAL SYSTEMS

KORU MEDICAL SYSTEMS, INC. ANNOUNCES APPOINTMENT

OF EDWARD WHOLIHAN TO ITS BOARD OF DIRECTORS

MAHWAH, NJ - October 4, 2023 - KORU

Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company

focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions

that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors

September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders.

"I am extremely proud to welcome a highly accomplished

executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and

success creating shareholder value in high-growth life science and healthcare businesses," said Linda Tharby, KORU Medical's

President and CEO. "As we continue to build our leadership position in the subcutaneous infusion market with our FREEDOM Infusion

System, Ed's insights will meaningfully contribute to our future growth and success."

Edward Wholihan joins KORU Medical's Board of

Directors with over 25 years of experience as Chief Financial Officer driving growth and shareholder value for public, private equity-sponsored,

and venture capital-funded life sciences and healthcare businesses. Most recently, he has leveraged his strategic management, financial,

and operational expertise consulting for various companies. Prior, he served as the Chief Financial Officer for Rarebreed Veterinary Partners,

Inc, a community of veterinary hospitals; CFO of Allena Pharmaceuticals, Inc., a development stage biopharmaceutical company; and CFO

of Medical Specialties Distributors, a leading solution provider to the specialty pharmacy, home infusion, and oncology practice markets

that was acquired by McKesson Corp (NYSE:MCK) in 2018. Ed also held two other CFO roles within the life science sector earlier in his

career and, prior to that, spent seven years as a management strategy consultant for McKinsey & Company. He earned his MBA from Stanford

University's Graduate School of Business and a BA in economics from Yale University.

"I am impressed with KORU Medical's tremendous

progress, innovation, and commitment toward growth, and I am excited to take part in helping the Company achieve its goal to improve the

quality of life for patients around the world," said Mr. Wholihan. "I look forward to supporting Linda and the KORU Medical

team as they continue to drive the Company's growth strategy and the provision of subcutaneous infusion therapies and their benefits

About KORU Medical Systems

KORU Medical Systems develops, manufactures, and commercializes

innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients around the world. The FREEDOM

Infusion System currently includes the FREEDOM60 and FreedomEdge Syringe Infusion Drivers, Precision Flow Rate Tubing

and HIgH-Flo Subcutaneous Safety Needle Sets . These devices are used for infusions administered in the home and alternate care

settings. For more information, please visit www.korumedical.com.